Home
About
Overview
Sharing Data
ORCID
Help
History (4)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
Identification of 4'-Demethyltangeretin as a Major Urinary Metabolite of Tangeretin in Mice and Its Anti-inflammatory Activities.
N-glycosylation augmentation of the cystic fibrosis epithelium improves Pseudomonas aeruginosa clearance.
Two distinct mechanisms of chromatin interaction by the Isw2 chromatin remodeling complex in vivo.
See All 4 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ, Usmani SZ. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol. 2018; 9:2134.
View in:
PubMed
subject areas
ADP-ribosyl Cyclase 1
Antibodies, Monoclonal
Antibody-Dependent Cell Cytotoxicity
Antineoplastic Agents, Immunological
Apoptosis
B-Lymphocytes, Regulatory
Drug Resistance, Neoplasm
Gene Expression Regulation, Neoplastic
Humans
Immunoglobulin Fc Fragments
Membrane Glycoproteins
Multiple Myeloma
Myeloid-Derived Suppressor Cells
Phagocytosis
Randomized Controlled Trials as Topic
T-Lymphocytes, Regulatory
Treatment Outcome
Tumor Microenvironment
authors with profiles
Saad Usmani MD